Remogliflozin etabonate improves fatty liver disease in diet-induced obese male mice
S Nakano, K Katsuno, M Isaji, T Nagasawa… - Journal of Clinical and …, 2015 - Elsevier
Background Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH) are
serious conditions and are being diagnosed at an increased rate. The etiology of these
hepatic disorders is not clear but involves insulin resistance and oxidative stress.
Remogliflozin etabonate (Remo) is an inhibitor of the sodium glucose-dependent renal
transporter 2 (SGLT2), and improves insulin sensitivity in type 2 diabetics. In the current
study, we examined the effects of Remo in a diet-induced obese mouse model of NAFLD …
serious conditions and are being diagnosed at an increased rate. The etiology of these
hepatic disorders is not clear but involves insulin resistance and oxidative stress.
Remogliflozin etabonate (Remo) is an inhibitor of the sodium glucose-dependent renal
transporter 2 (SGLT2), and improves insulin sensitivity in type 2 diabetics. In the current
study, we examined the effects of Remo in a diet-induced obese mouse model of NAFLD …